Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C
- PMID: 3408273
- DOI: 10.1007/BF00931548
Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C
Abstract
Thirty-three women (22-38 years old) with polycystic ovarian disease (PCOD) were included in this study. The criteria for diagnosis were: an LH/FSH ratio greater than 2.0; polycystic ovaries, diagnosed by means of palpation and ultrasound; androgenism and menstrual cycle abnormalities. Using endocrine parameters, we attempted to define distinct forms of PCOD. The patients were placed in three groups according to serum levels of testosterone (T) and 17 alpha-hydroxyprogesterone (17 alpha OHP) and the estrone/androstendione (E1/delta 4A) ratio. Patients in group I (n = 18) had an elevated T level (greater than 1.0 ng/ml) and a 17 alpha OHP level under 4.0 ng/ml. This type of POCD was called the "androgen" type. Patients in group II (n = 7) had normal T- and 17 alpha OHP levels under 4.0 ng/ml and an elevated (E1/delta 4A) ratio. This type of PCOD was called the "estrogen" type. Group III (n = 8) comprised patients with 17 alpha OHP levels over 4.0 ng/ml. This type of PCOD was called the "adrenocortical" type. In two patients of this group, a modified ACTH test revealed late-onset congenital hyperplasia. The endocrine parameters of the patients with PCOD were compared with those of 17 adult without signs of PCOD. Statistical evaluation was done by variance analysis. Women with acromegaly often show signs of androgenism as well as menstrual cycle abnormalities. This may indicate an association between the growth factors human growth hormone (HGH) and somatomedin-C (Sm-C) and the biosynthese and metabolism of steroid hormone. Recent experiments have demonstrated such associations. Our study showed an association between the HGH and Sm-C levels and abnormal steroid hormone concentrations in women with androgen type PCOD (group I). These patients had a significantly decreased HGH level, a significantly decreased HGH/Sm-C ratio, and an increased average Sm-C level. These data suggest that elevated Sm-C levels can, by a negative-feedback mechanism, inhibit pituitary HGH production. We discuss the possible mechanisms causing elevation of plasma Sm-C, HGH, steroid hormones, excessive food intake, and possibly prolactin seem responsible for the clinical manifestation of increased Sm-C production in adolescence and for its level in the fertile years of patients.
Similar articles
-
Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease.Fertil Steril. 1989 Jun;51(6):972-5. doi: 10.1016/s0015-0282(16)60728-8. Fertil Steril. 1989. PMID: 2542098
-
Effect of the variations of female sex hormones during the menstrual cycle upon serum somatomedin and growth-promoting activity.Horm Res. 1986;23(1):31-7. doi: 10.1159/000180285. Horm Res. 1986. PMID: 3079724
-
Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.Fertil Steril. 1992 Oct;58(4):697-702. doi: 10.1016/s0015-0282(16)55314-x. Fertil Steril. 1992. PMID: 1426312
-
Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis.Endocrinol Metab Clin North Am. 1993 Mar;22(1):75-92. Endocrinol Metab Clin North Am. 1993. PMID: 8095452 Review.
-
Selected aspects of polycystic ovarian disease.Endocrinol Metab Clin North Am. 1992 Mar;21(1):141-71. Endocrinol Metab Clin North Am. 1992. PMID: 1533584 Review.
Cited by
-
Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.J Endocrinol Invest. 1997 Apr;20(4):220-4. doi: 10.1007/BF03346907. J Endocrinol Invest. 1997. PMID: 9211130
-
GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.J Endocrinol Invest. 2003 Feb;26(2):117-22. doi: 10.1007/BF03345138. J Endocrinol Invest. 2003. PMID: 12739737
-
Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells.J Clin Invest. 1990 Aug;86(2):560-5. doi: 10.1172/JCI114745. J Clin Invest. 1990. PMID: 2384603 Free PMC article.
-
[Growth factors, carbohydrate and lipid metabolism in females with polycystic ovary syndrome].Arch Gynecol Obstet. 1989;245(1-4):990-2. doi: 10.1007/BF02417651. Arch Gynecol Obstet. 1989. PMID: 2679448 German. No abstract available.
-
Growth hormone cotreatment with gonadotropins in ovulation induction.J Endocrinol Invest. 1996 Dec;19(11):763-79. doi: 10.1007/BF03347881. J Endocrinol Invest. 1996. PMID: 9061511 Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical